

CPT® Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

Most recent changes to the CPT® Category I New Immunization* Vaccine Codes Long Descriptor document:

- Addition of 1 Category I code (90593) accepted by the CPT Editorial Panel at the September 2024 meeting.

The pertinent guidelines and parenthetical notes addressing the COVID-19 administration and product codes scheduled for deletion on November 1, 2023 have been added to this document and includes the following:

- Addition of revised Evaluation and Management and Medicine guidelines that include immunization codes 90480, 91304, 91318, 91319, 91320, 91321, and 91322.
- Deletion of codes 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A, 91300, 91301, 91302, 91303, 91305, 91306, 91307, 91308, 91309, 91310, 91311, 91312, 91313, 91314, 91315, 91316, and 91317 throughout the code set.
- Deletion of Appendix Q table.

*For the purposes of CPT coding, “Immunization” includes vaccines/toxoids, immune globulins, serum or recombinant products.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions” may result in gaps in code number sequencing.

The following vaccine codes were accepted at the September 2023 CPT Editorial Panel meeting for the 2025 CPT production cycle. These codes are effective on July 1, 2024, following the six-month implementation period which begins January 1, 2024.

***Note that codes 90637 and 90638 will follow code 90694.**

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
#●90637	Influenza virus vaccine, quadrivalent (qIRV), mRNA; 30 mcg/0.5 mL dosage, for intramuscular use	December 28, 2023	July 1, 2024	CPT® 2025
#●90638	60 mcg/0.5 mL dosage, for intramuscular use	December 28, 2023	July 1, 2024	CPT® 2025

The removal of the FDA pending symbol follows notification that these products have been granted FDA approval status on the date indicated. Codes 90589 and 90623 were originally published in CPT 2024.

***Note that code 90589 will follow code 90586 and code 90623 will follow 90619.**

Codes	Long Descriptor	Released to AMA Website	FDA Approval Effective	Publication
#●90589	Chikungunya virus vaccine, live attenuated, for intramuscular use	June 30, 2023	November 9, 2023	CPT® 2025
#●90623	Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use	June 30, 2023	October 20, 2023	CPT® 2025

CPT® Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

The following immunization codes were accepted by the CPT Editorial Panel. Codes 90480, 91318, 91319, 91320, 91321, 91322 are effective on September 11, 2023.

*Note that code 90480 will follow code 90474 and codes 91304, 91318, 91319, 91320, 91321, 91322 will precede 90476.

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
	<p>Evaluation and Management Preventive Medicine Services</p> <p>► Vaccine/toxoid products, immunization administrations, ancillary studies involving laboratory, radiology, other procedures, or screening tests (eg, vision, hearing, developmental) identified with a specific CPT code are reported separately. For immunization administration and vaccine risk/benefit counseling, see 90460, 90461, 90471-90474, 90480, 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A. For vaccine/toxoid products, see 90476-90759, <u>91304, 91318, 91319, 91320, 91321, 91322</u>91300-91317. ◀</p>	<p>Revised Guidelines Released to AMA Website</p> <p>October 24, 2023</p>	<p>Revised Guidelines Effective</p> <p>November 1, 2023</p>	<p>Revised Guidelines Publication</p> <p>CPT® 2025</p>
	<p>Medicine Immunization Administration for Vaccines/Toxoids</p> <p>► Report immunization administration codes (90460, 90461, 90471-90474, 90480, 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A) in addition to the vaccine and toxoid code(s) (90476-90759, <u>91304, 91318, 91319, 91320, 91321, 91322-91300-91317</u>).</p> <p>Report codes 90460 and 90461 only when the physician or other qualified health care professional provides face-to-face counseling of the patient/family during the administration of a vaccine other than when performed for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccines. For immunization administration of any vaccine, other than SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines, that is not accompanied by face-to-face physician or other qualified health care professional counseling to the patient/family/guardian or for administration of vaccines to patients over 18 years of age, report 90471-90474. (See also Instructions for Use of the CPT Codebook for definition of reporting qualifications.) ◀</p> <p>► Report 90480, 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A,</p>	<p>Revised Guidelines Released to AMA Website</p> <p>October 24, 2023</p>	<p>Revised Guidelines Effective</p> <p>November 1, 2023</p>	<p>Revised Guidelines Publication</p> <p>CPT® 2025</p>

CPT® Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A for immunization administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines only. This code is used for administration and counseling that involves the use of COVID-19 vaccines for immunization against contracting the disease. This includes administration of COVID-19 vaccine for all age populations. Each administration code is specific to each individual vaccine product (eg, 91300-91317), the dosage schedule (eg, first dose, second dose), and counseling, when performed. The appropriate administration code is chosen based on the type of vaccine and the specific dose number the patient receives in the schedule. For example, 0012A is reported for the second dose of vaccine 91301. Do not report 90460-90474 for the administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines. Codes related to SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine administration are listed in Appendix Q, with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), National Drug Code (NDC) Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code descriptor and must be the vaccine represented by the manufacturer and vaccine name listed in Appendix Q. ◀			
90460	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered			
+90461	<p>each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)</p> <p>(Use 90460 for each vaccine administered. For vaccines with multiple components [combination vaccines], report 90460 in conjunction with 90461 for each additional component in a given vaccine)</p> <p>▶ (Do not report 90460, 90461 in conjunction with 91304, 91318, 91319, 91320, 91321, 91322-91300-91317, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter) ◀</p>	<p>Revised Parenthetical Released to AMA Website</p> <p>October 24, 2023</p>	<p>Revised Parenthetical Effective</p> <p>November 1, 2023</p>	<p>Revised Parenthetical Publication</p> <p>CPT® 2025</p>
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) (Do not report 90471 in conjunction with 90473)			
+90472	<p>each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)</p> <p>(Use 90472 in conjunction with 90460, 90471, 90473)</p> <p>▶ (Do not report 90471, 90472 in conjunction with 91304, 91318, 91319, 91320, 91321, 91322-91300-91317, unless both a severe acute respiratory syndrome coronavirus 2</p>	<p>Revised Parenthetical Released to AMA Website</p> <p>October 24, 2023</p>	<p>Revised Parenthetical Effective</p> <p>November 1, 2023</p>	<p>Revised Parenthetical Publication</p> <p>CPT® 2025</p>

CPT® Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	[SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter) ◀			
90473	Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid) (Do not report 90473 in conjunction with 90471)			
✚90474	each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) (Use 90474 in conjunction with 90460, 90471, 90473) ▶ (Do not report 90473, 90474 in conjunction with 91304, 91318, 91319, 91320, 91321, 91322-91300-91317, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter) ◀	Revised Parentheticals Released to AMA Website October 24, 2023	Revised Parenthetical Effective November 1, 2023	Revised Parenthetical Publication CPT® 2025
#●90480	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose ▶ (Report 90480 for the administration of vaccine 91304, 91318, 91319, 91320, 91321, 91322) ◀ ▶ (Do not report 90480 in conjunction with 90476-90759) ◀	August 14, 2023	September 11, 2023	CPT® 2025
	▶ (0001A, 0002A, 0003A, 0004A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0051A, 0052A, 0053A, 0054A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0121A, 0124A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0071A, 0072A, 0073A, 0074A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0151A, 0154A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0081A, 0082A, 0083A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0171A, 0172A, 0173A, 0174A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0011A, 0012A, 0013A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0064A has been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0134A has been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0141A, 0142A, 0144A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀	August 14, 2023	November 1, 2023	CPT® 2025

CPT® Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	<p>► (0091A, 0092A, 0093A, 0094A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀</p> <p>► (0021A, 0022A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀</p> <p>► (0031A, 0034A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀</p> <p>► (0041A, 0042A, 0044A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀</p> <p>► (0104A has been deleted. To report administration of COVID-19 vaccine, use 90480) ◀</p> <p>► (0111A, 0112A, 0113A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀</p> <p>► (0164A has been deleted. To report administration of COVID-19 vaccine, use 90480) ◀</p>			
	<p>Vaccines, Toxoids</p> <p>► Codes 90476-90759, <u>91304, 91318, 91319, 91320, 91321, 91322-91300-91317</u> identify the vaccine product only. To report the administration of a vaccine/toxoid other than SARS-CoV-2 (coronavirus disease [COVID-19]), the vaccine/toxoid product codes (90476-90759) must be used in addition to an immunization administration code(s) (90460, 90461, 90471, 90472, 90473, 90474). To report the administration of a SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine, the vaccine/toxoid product codes (<u>91304, 91318, 91319, 91320, 91321, 91322-91300-91317</u>) should be reported with the corresponding immunization administration codes (<u>90480, 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A</u>). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC-Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code descriptor and must be the vaccine represented by the manufacturer and vaccine name listed in Appendix Q. ◀</p> <p>► Do not report 90476-90759 in conjunction with the SARS-CoV-2 (coronavirus disease [COVID-19]) immunization administration codes <u>90480, 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A</u>, unless both a SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter. ◀</p>	<p>Revised Guidelines Released to AMA Website</p> <p>October 24, 2023</p>	<p>Revised Guidelines Effective</p> <p>November 1, 2023</p>	<p>Revised Guidelines Publication</p> <p>CPT® 2025</p>

CPT® Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	<p>► Modifier 51 should not be reported with vaccine/toxoid codes 90476-90759, <u>91304, 91318, 91319, 91320, 91321, 91322-91300-91317</u>, when reported in conjunction with administration codes 90460, 90461, 90471, 90472, 90473, 90474, <u>90480-0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A.</u> ◀</p>			
	<p>Separate codes are available for combination vaccines (eg, Hib-HepB, DTap-IPV/Hib). It is inappropriate to code each component of a combination vaccine separately. If a specific vaccine code is not available, the unlisted procedure code should be reported, until a new code becomes available.</p> <p>► The vaccine/toxoid abbreviations listed in codes 90476-90759, <u>91304, 91318, 91319, 91320, 91321, 91322-91300-91317</u> reflect the most recent US vaccine abbreviation references used in the Advisory Committee on Immunization Practices (ACIP) recommendations at the time of CPT code set publication. Interim updates to vaccine code descriptors will be made following abbreviation approval by the ACIP on a timely basis via the AMA CPT website (ama-assn.org/cpt-cat-i-immunization-codes). The accuracy of the ACIP vaccine abbreviation designations in the CPT code set does not affect the validity of the vaccine code and its reporting function. ◀</p> <p>► For the purposes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccinations, codes 0003A, 0013A, 0053A, 0073A, 0083A, 0093A, 0113A, and 0173A represent the administration of a third dose in the primary series (eg, patient with immunocompromising condition or patient age 6 months through 4 years). In contrast, the booster or additional dose codes 0004A, 0034A, 0044A, 0054A, 0064A, 0074A, 0094A, 0104A, 0124A, 0134A, 0144A, 0154A, 0164A, and 0174A represent the administration of a dose of vaccine when the initial immune response to a primary vaccine series was sufficient, but has likely waned over time. ◀</p>	<p>Revised and Deleted Guidelines Released to AMA Website</p> <p>October 24, 2023</p>	<p>Revised and Deleted Guidelines Effective</p> <p>November 1, 2023</p>	<p>Revised and Deleted Guidelines Publication</p> <p>CPT® 2025</p>
	<p>► (91300 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91305 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91312 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91307 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease</p>	<p>August 14, 2023</p>	<p>November 1, 2023</p>	<p>CPT® 2025</p>

CPT[®] Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	<p>{COVID-19} vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91315 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91308 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91317 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91301 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91306 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91313 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91314 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91311 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91316 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91309 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91302 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>► (91303 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p>			
--	--	--	--	--

CPT® Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

#▲91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative-free, 5 mcg/0.5 mL dosage, for intramuscular use ► (Report 91304 with administration codes <u>90480</u> , 0041A, 0042A, 0044A) ◀	August 14, 2023	Revised Code Effective: August 14, 2023 Revised Parenthetical Note Effective: September 11, 2023	CPT® 2025
	► (91310 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀	August 14, 2023	November 1, 2023	CPT® 2025
#●91318	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.23 mL dosage, tris-sucrose formulation, for intramuscular use ► (Report 91318 with administration code 90480) ◀	August 14, 2023 Technical Correction Released to AMA Website: September 8, 2023	September 11, 2023	CPT® 2025
#●91319	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.23 mL dosage, tris-sucrose formulation, for intramuscular use ► (Report 91319 with administration code 90480) ◀	August 14, 2023 Technical Correction Released to AMA Website: September 8, 2023	September 11, 2023	CPT® 2025
#●91320	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use ► (Report 91320 with administration code 90480) ◀	August 14, 2023	September 11, 2023	CPT® 2025
#●91321	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use ► (Report 91321 with administration code 90480) ◀	August 14, 2023	September 11, 2023	CPT® 2025
#●91322	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use ► (Report 91322 with administration code 90480) ◀	August 14, 2023	September 11, 2023	CPT® 2025
90476	Adenovirus vaccine, type 4, live, for oral use			

CPT® Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

96372	<p>Therapeutic, Prophylactic, and Diagnostic Injections and Infusions (Excludes Chemotherapy and Other Highly Complex Drug or Highly Complex Biologic Agent Administration)</p> <p>Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular</p> <p>► (For administration of vaccines/toxoids, see 90460, 90461, 90471, 90472, 90473, 90474, 90480-0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A) ◀</p>	<p>Revised Parenthetical Released to AMA Website</p> <p>October 24, 2023</p>	<p>Revised Parenthetical Effective</p> <p>November 1, 2023</p>	<p>Revised Parenthetical Publication</p> <p>CPT® 2025</p>
	<p>Appendix Q</p> <p>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines</p> <p>► <u>The crosswalk of COVID-19 vaccine and administration codes and their associated patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses instructions (formerly Appendix Q) have been removed from the CPT code set. For information and guidance to report COVID-19 immunization services, refer to the E/M and Medicine section guidelines. This table links the individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine product codes (91300-91317) to their associated immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A), patient age, manufacturer name, vaccine name(s), 10- and 11-digit National Drug Code (NDC) Labeler Product ID, and interval between doses. These codes are also located in the Medicine section of the CPT code set.</u></p> <p><u>Additional introductory and instructional information for codes 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A and 91300-91317 can be found in the Immunization Administration for Vaccines/Toxoids and Vaccines, Toxoids guidelines in the Medicine section of the CPT code set. ◀</u></p>	<p>New and Revised Guidelines Released to AMA Website</p> <p>August 14, 2023</p>	<p>New and Revised Guidelines Effective</p> <p>November 1, 2023</p>	<p>New and Revised Guidelines Publication</p> <p>CPT® 2025</p>

CPT® Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

The following immunization administration codes were accepted at the September 2023 CPT Editorial Panel meeting for the 2025 production cycle. Codes 96380, 96381 are effective on October 6, 2023.

*Note that codes 96380 and 96381 will follow code 96377.

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
#●96380	Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection, with counseling by physician or other qualified health care professional ► (Report 96380 for administration of respiratory syncytial virus, monoclonal antibody, seasonal dose [90380, 90381]) ◀	October 6, 2023	October 6, 2023	CPT® 2025
#●96381	Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection ► (Report 96381 for administration of respiratory syncytial virus, monoclonal antibody, seasonal dose [90380, 90381]) ◀	October 6, 2023	October 6, 2023	CPT® 2025

The following vaccine code was accepted at the February 2024 CPT Editorial Panel meeting for the 2025 CPT production cycle. This code became effective June 17, 2024.

*Note that code 90684 will follow code 90677.

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
# ● 90684	Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use	May 23, 2024 FDA Symbol Removal Released to AMA Website June 20, 2024	June 17, 2024	CPT® 2025

The removal of the FDA pending symbol follows notification that this product has been granted FDA approval status on the date indicated. Code 90683 was originally published in CPT 2024.

*Note that code 90683 will follow code 90679.

Codes	Long Descriptor	Released to AMA Website	FDA Approval Effective	Publication of Code with FDA Symbol Removed
# ● 90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use	June 4, 2024	May 31, 2024	CPT® 2025

The following vaccine code revision was accepted at the February 2024 CPT Editorial Panel meeting for the 2025 CPT production cycle. This code revision is effective on January 1, 2025, following the six-month implementation period which begins July 1, 2024.

CPT[®] Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
▲90661	Influenza virus vaccine, trivalent (ccIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	July 1, 2024	January 1, 2025	CPT [®] 2025
The following vaccine code was accepted at the May 2024 CPT Editorial Panel meeting for the 2025 CPT production cycle. This code is effective on October 1, 2024, following the three-month implementation period which begins July 1, 2024. *Note that code 90624 will follow code 90623.				
Codes	Long Descriptor	Released to AMA Website	Effective	Publication
#/●90624	Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use	July 1, 2024	October 1, 2024	CPT [®] 2025
The following vaccine code was accepted at the September 2024 CPT Editorial Panel meeting for the 2026 CPT production cycle. This code is effective on January 1, 2025, following the three-month implementation period which begins October 18, 2024. *Note that code 90593 will follow code 90589.				
Codes	Long Descriptor	Released to AMA Website	Effective	Publication
#/●90593	Chikungunya virus vaccine, recombinant, for intramuscular use	October 18, 2024	January 1, 2025	CPT [®] 2026